Comparison of the absorption of micronized (Daflon 500 mg) and nonmicronized 14C-diosmin tablets after oral administration to healthy volunteers by accelerator mass spectrometry and liquid scintillation counting.
Daflon 500 mg, is a micronized purified flavonoid fraction, containing 90% w/w diosmin and 10% w/w of flavonoids expressed as hesperidin, used clinically in the treatment of chronic venous insufficiency and hemorrhoidal disease. This study was designed to investigate the influence of particle size on the overall absorption of diosmin after oral administration of micronized (mean particle size = 1.79 microm, with 80% of particles having a size lower than 3.45 microm) and nonmicronized diosmin (mean particle size = 36.5 microm, with 80% of particles comprised between 19.9 and 159 microm). In a double blinded, cross-over study design, 500 mg tablets containing trace amounts (approximately 25 nCi) of (14)C-diosmin were administered to 12 healthy male volunteers as a single oral dose. Accelerator mass spectrometry and liquid scintillation counting were used for the measurement of (14)C-diosmin in urine and feces. Absorption of (14)C-diosmin from the gastrointestinal tract, measured by the urinary excretion of total radioactivity, was significantly improved with the micronized (57.9 +/- 20.2%) compared with the nonmicronized material (32.7 +/- 18.8%). Statistical comparison of the urinary excretion of the two pharmaceutical formulations showed this difference to be highly significant (p = 0.0004, analysis of variance). The overall excretion of the radiolabeled dose was 100% with mean +/- SD of 109 +/- 23% and 113 +/- 20% for the micronized and nonmicronized forms, respectively. The results of this study show: 1. the impact of a reduction of particle size on the extent of absorption of diosmin, giving a pharmacokinetic explanation to the better clinical efficacy observed with the micronized formulation, and 2. the use of accelerator mass spectrometry in conjunction with liquid scintillation counting in measurement of bioavailability in a human cross-over study comparing two drug formulations containing trace amounts of radioactivity.
Garner
R C
RC
The Centre for Biomedical Accelerator Mass Spectrometry (CBAMS Ltd.) Sand Hutton, York Y041 ILZ, United Kingdom. colin.garner@cbams.co.uk
Garner
J V
JV
Gregory
S
S
Whattam
M
M
Calam
A
A
Leong
D
D
D000284:Administration, Oral; D000328:Adult; D000704:Analysis of Variance; D002250:Carbon Radioisotopes / Q000493:pharmacokinetics / Q000652:urine; D002626:Chemistry, Pharmaceutical; D018592:Cross-Over Studies; D004145:Diosmin / Q000737:chemistry / Q000493:pharmacokinetics* / Q000652:urine; D004311:Double-Blind Method; D005243:Feces / Q000737:chemistry; D006801:Humans; D007408:Intestinal Absorption; D008297:Male; D013058:Mass Spectrometry / Q000379:methods; D008875:Middle Aged; D010315:Particle Accelerators / Q000295:instrumentation; D010316:Particle Size; D012588:Scintillation Counting / Q000379:methods*; D013607:Tablets
D002250:Carbon Radioisotopes; D013607:Tablets; D004145:Diosmin